CN Patent

CN107115344B — 酪氨酸激酶抑制剂在制备用于预防和/或治疗纤维化疾病的药物中的用途

Assigned to Guangdong Zhongsheng Ruichuang Biotechnology Co Ltd · Expires 2019-06-14 · 7y expired

What this patent protects

本发明涉及酪氨酸激酶抑制剂在制备用于预防和/或治疗纤维化疾病的药物中的用途。具体涉及式II所示的化合物或其药学上可接受的盐在制备治疗和/或预防纤维化疾病的药物中的应用，

USPTO Abstract

本发明涉及酪氨酸激酶抑制剂在制备用于预防和/或治疗纤维化疾病的药物中的用途。具体涉及式II所示的化合物或其药学上可接受的盐在制备治疗和/或预防纤维化疾病的药物中的应用，

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN107115344B
Jurisdiction: CN
Classification: —
Expires: 2019-06-14
Drug substance claim: No
Drug product claim: No
Assignee: Guangdong Zhongsheng Ruichuang Biotechnology Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.